Original Source(s)
Related Content
FDA Expands CAPVAXIVE Pediatric Use
Phase 3 data showed noninferior immune responses vs pneumococcal 23-valent polysaccharide vaccine in pediatric patients at increased risk.
June 18, 2026
-
2 min